首頁 > 市場調查報告書 > 製藥

處方藥

市場調查報告書

商品編碼

2148715

代謝疾病胜肽類藥物市場：依給藥途徑、合成技術、通路及地區分類

Peptide Therapeutics In Metabolic Disorders Market, By Route Of Administration, By Synthesis Technology, By Distribution Channels, By Geography

出版日期: 2026年09月28日 | 出版商:

Coherent Market Insights | 英文 257 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，用於治療代謝疾病的胜肽類藥物市場規模將達到 393 億美元，到 2033 年將達到 478 億美元。預計 2026 年至 2033 年的複合年成長率將達到 14.6%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	393億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	14.60%	2033年市場規模預測：	478億美元

肽類療法在治療糖尿病、肥胖症及相關代謝性疾病方面發揮日益重要的作用。這些療法可針對調節血糖值、食慾、胰島素活性和能量代謝的生物路徑。這些疾病的日益普及以及對有效長期治療方案不斷成長的需求，正推動製藥公司開發基於胜肽的療法。同時，胜肽工程、藥物傳遞和製劑技術的進步，使研發人員能夠提高胜肽類療法的療效，並拓展其在代謝性疾病治療中的應用範圍。

製藥公司正在開發新一代胜肽療法，以提高療效、延長作用持續時間並提升患者用藥便利性。包括GLP-1、雙受體促效劑和多受體促效劑在內的腸促胰素療法，正在擴展胜肽類藥物在代謝性疾病治療的應用。研究人員也積極推動口服給藥系統、緩釋製劑、聯合治療以及新型分子標靶的研究。這些創新正在拓展治療選擇，並刺激對臨床開發、生產能力和先進胜肽類治療平台的投資。

市場動態

隨著糖尿病、肥胖症和其他代謝性疾病的日益普遍，對有效治療方法的需求也持續成長。醫療專業人員正在尋求能夠支持疾病永續管理並改善患者預後的療法。針對特定代謝路徑的胜肽類療法持續吸引臨床關注。製藥公司正在擴大其研究項目，開發創新的胜肽療法，以滿足糖尿病、肥胖及相關代謝性疾病領域尚未滿足的醫療需求。

胜肽工程、分子設計、藥物傳遞和製劑技術的進步正在提高治療效果和患者用藥便利性。研發人員正在開發長效製劑、口服給藥系統、聯合治療和多標靶分子，以增強治療效果。繼腸促胰素療法取得成功之後，製藥公司正在進一步研究生物標的和治療組合。這些創新正在拓展胜肽的應用範圍，並吸引更多投資進入開發平臺。

製藥公司在胜肽類療法的研發和生產過程中面臨許多挑戰。複雜的分子結構、穩定性要求、特殊的生產流程以及嚴格的品管標準都增加了研發的複雜性。研發公司必須進行廣泛的臨床試驗，以確定其長期安全性和有效性。替代療法的存在以及患者依從性的擔憂也影響著競爭格局。能夠改善藥物遞送、提高生產效率、延長治療療程並提升患者便利性的公司，可望鞏固其在代謝疾病治療領域的地位。

本次調查的主要特點

該研究重點關注各個細分市場的潛在商機，並為參與代謝疾病胜肽類藥物市場的相關相關人員提供有吸引力的投資提案矩陣。
本研究深入分析了市場促進因素、限制因素、機會、新興胜肽技術、藥物輸送技術進步、腸促胰素療法、治療創新、臨床開發趨勢、區域展望以及主要市場參與企業採取的競爭策略。
本研究基於公司簡介、治療組合、研發管線分析、最新進展、臨床進展、財務績效和策略舉措，對代謝疾病肽類藥物市場的主要參與者進行了分析。
透過利用本報告中提出的見解，製藥公司、生技公司、醫療保健提供者、投資者、研究人員和經營團隊可以就藥物開發、胜肽創新、臨床研究、生產投資、市場擴張、策略聯盟和治療藥物商業化做出明智的決策。
《代謝疾病胜肽療法市場》報告的目標受眾廣泛，包括投資者、製藥公司、生物技術公司、合約開發和生產組織 (CDMO)、醫療保健提供者、研究機構、技術開發商、新市場參與企業和金融相關人員。
相關人員透過《代謝疾病胜肽類藥物市場》報告中提出的分析框架、競爭基準、治療管線評估、治療應用分析、區域評估和市場評估矩陣做出明智的策略決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- PolyPeptide Group
- Eli Lilly and Company
- Bachem Holding AG
- Takeda Pharmaceuticals Co. Ltd.
- Ipsen SA
- Rhythm Pharmaceuticals Inc.
- Novo Nordisk A/S.
分析師意見

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2003

Peptide Therapeutics In Metabolic Disorders Market is estimated to be valued at USD 39.3 Bn in 2026 and is expected to reach USD 47.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 39.3 Bn
Historical Data for:	2020 to 2024	Forecast Period:	2026 to 2033
Forecast Period 2026 to 2033 CAGR:	14.60%	2033 Value Projection:	USD 47.8 Bn

Peptide therapeutics play an increasingly important role in treating metabolic disorders such as diabetes, obesity, and related conditions. These therapies target biological pathways that regulate glucose levels, appetite, insulin activity, and energy metabolism. Rising disease prevalence and demand for effective long-term treatments encourage pharmaceutical companies to advance peptide-based therapies. Meanwhile, improvements in peptide engineering, drug delivery, and formulation technologies help developers enhance treatment performance and expand the use of peptide therapeutics in metabolic disease management.

Pharmaceutical companies are developing next-generation peptide therapies that improve treatment effectiveness, durability, and patient convenience. Incretin-based therapies, including GLP-1 and dual- or multi-receptor agonists, have expanded the use of peptide medicines in metabolic care. Researchers are also advancing oral delivery systems, extended-release formulations, combination therapies, and novel molecular targets. These innovations are broadening treatment options and driving investment in clinical development, manufacturing capacity, and advanced peptide-based therapeutic platforms.

Market Dynamics

The rising prevalence of diabetes, obesity, and other metabolic disorders continues to increase demand for effective treatments. Healthcare providers seek therapies that support durable disease management and improve patient outcomes. Peptide therapeutics target specific metabolic pathways and continue to gain clinical interest. Pharmaceutical companies are expanding research programs and developing innovative peptide-based therapies to address unmet treatment needs across diabetes, obesity, and related metabolic conditions.

Advances in peptide engineering, molecular design, drug delivery, and formulation technologies are improving therapeutic performance and patient convenience. Developers are creating longer-acting formulations, oral delivery systems, combination therapies, and multi-target molecules to enhance treatment outcomes. The success of incretin-based therapies has encouraged pharmaceutical companies to investigate additional biological targets and treatment combinations. These innovations are expanding peptide applications and attracting greater investment across the development pipeline.

Pharmaceutical companies face several challenges when developing and manufacturing peptide therapeutics. Complex molecular structures, stability requirements, specialized production processes, and strict quality-control standards can increase development complexity. Developers must conduct extensive clinical studies to establish long-term safety and efficacy. Alternative treatment options and patient adherence concerns also influence competition. Companies that improve drug delivery, manufacturing efficiency, treatment duration, and patient convenience can strengthen their position in metabolic disorder treatment.

Key Features of the Study

It highlights potential revenue opportunities across various market segments and provides attractive investment proposition matrices for stakeholders involved in the Peptide Therapeutics in Metabolic Disorders Market.
This study offers key insights into market drivers, restraints, opportunities, emerging peptide technologies, drug delivery advancements, incretin-based therapies, therapeutic innovations, clinical development trends, regional outlook, and competitive strategies adopted by leading market participants.
It profiles key players in the Peptide Therapeutics in Metabolic Disorders Market based on company overview, therapeutic portfolio, pipeline analysis, recent developments, clinical advancements, financial performance, and strategic initiatives.
Key companies covered as part of this study include AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.
Insights from this report enable pharmaceutical companies, biotechnology firms, healthcare providers, investors, researchers, and management teams to make informed decisions regarding drug development, peptide innovation, clinical research, manufacturing investments, market expansion, strategic collaborations, and therapeutic commercialization.
The Peptide Therapeutics in Metabolic Disorders Market report serves a wide range of stakeholders, including investors, pharmaceutical companies, biotechnology companies, contract development and manufacturing organizations, healthcare providers, research institutions, technology developers, new market entrants, and financial analysts.
Stakeholders can make well-informed strategic decisions through the analytical frameworks, competitive benchmarking, therapeutic pipeline assessment, treatment application analysis, regional evaluation, and market evaluation matrices presented in the Peptide Therapeutics in Metabolic Disorders Market report.

Market Segmentation

By Route Of Administration (Revenue, USD Bn, 2021-2033)
- Intravenous
- Oral
- Nasal
- Others
By Synthesis Technology (Revenue, USD Bn, 2021-2033)
- Solid Phase Peptide Synthesis
- Liquid Phase Peptide Synthesis
- Hybrid Technology
By Distribution Channels (Revenue, USD Bn, 2021-2033)
- Hospitals
- Specialty Clinics
- Retail Pharmacy
- Online Pharmacy
By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- PolyPeptide Group
- Eli Lilly and Company
- Bachem Holding AG
- Takeda Pharmaceuticals Co. Ltd.
- Ipsen S.A
- Rhythm Pharmaceuticals Inc.
- Novo Nordisk A/S.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Route of Administration
- Market Snapshot, By Synthesis Technology
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Peptide Therapeutics In Metabolic Disorders Market, By Route of Administration, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Peptide Therapeutics In Metabolic Disorders Market, By Synthesis Technology, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Solid Phase Peptide Synthesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Liquid Phase Peptide Synthesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Hybrid Technology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Peptide Therapeutics In Metabolic Disorders Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Peptide Therapeutics In Metabolic Disorders Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- AstraZeneca plc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Sanofi S.A.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- PolyPeptide Group
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Bachem Holding AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Takeda Pharmaceuticals Co. Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Ipsen S.A
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Rhythm Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novo Nordisk A/S.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views